

Society for Investigative Dermatology: 2021 Society Business



The Society for Investigative Dermatology
30 April 2021
Held via Zoom Meeting

Present: Janet Fairley, MD, Nicole Ward, PhD, Mark S. Udey, MD/PhD, Maryam Asgari, MD, Russell Hall, MD, Andrew Kowalczyk, PhD, Paul Nghiem, MD/PhD, Dan Kaplan, MD/PhD, Heidi Jacobs, MD, Niro Anandasabapathy, MD/PhD, JP Therrien, PhD, Sam Hwang, MD/PhD, Lisa Beck, MD, Luis Garza, MD/PhD, Maria Morasso, PhD, Suephy Chen, MD, Sewon Kang, MD, Natasha Hill, PhD, Anj Dlugosz, MD/PhD, Jim Rumsey, Becky Minnillo, DM/MPA, and Elizabeth Blalock.

Unable to Attend: Ponciano Cruz, MD and Allison Billi, MD/PhD.

Invited Guests: Leandra Barnes, MD, Russ Hall, MD, Aimee Payne, MD/PhD, Cassandra Quave, PhD, Lloyd Miller, MD/PhD, and Valentina Greco, PhD.

Janet Fairley, MD, Society for Investigative Dermatology (SID) President, called the meeting to order and welcomed the members to the virtual meeting. A motion to approve the meeting minutes from the Virtual Fall 2020 Board Meeting was made, seconded, and approved. She then asked the Board whether anyone had any conflict of interest (COI) declarations to make or amend. None were declared. As requested at the fall meeting, a link to the COI form was sent out to the Board before the meeting.

Dr Fairley reminded the members that on the basis of their feedback, the board materials were now divided into a Consent Agenda—an information-only document and an Agenda with materials that required more scrutiny and discussion. This is intended to help prioritize the weightier elements of the agenda.

Journal

Mark Udey, MD/PhD, *Journal of Investigative Dermatology* (JID) Editor, gave the Board an update regarding journal activities. He shared that the COVID-19 pandemic had no real impact on submissions; they were up 16% to 2020. He is pleased with the current turnaround time of fewer than 30 days. The JID was maintaining a 30–35% acceptance rate, and the impact factor (IF) had risen to 7.143. The 2020 IF listing is expected in June.

He stated that it is hard to know exactly which articles will be highly cited. His plan is to identify topics for reviews/authors to increase the IF. They will also leverage social media to drive traffic and increase the visibility and sharing of articles. The three JID Social Media Editors will work to promote content. There is speculation that Clarivate may change the calculation for IF soon..., so it is a shifting landscape.

The journal is looking for industry support for a technology enhancement for the Research Techniques Made Simple (RTMS) section. To identify and publish impactful manuscripts, the journal employs a Rapid Review process, with the goal of publication within 30 days.

There was some discussion about a potential transition of the JID to OA. It was noted that many funders are pushing for publication in a fully OA journal. The JID does offer the option of OA immediately for authors if they pay a fee. External pressure will compel Elsevier to revise their current policies, including those related to print publication, page/image charges, etc. Funders appear to hold all the cards. The board of directors (BOD) asked whether an abstract could be included in Letters to the Editor, for them to be more discoverable (i.e., the abstract can be read even without a subscription to the journal); this might make them more likely to be cited. Will adding an abstract, which might indeed make them more discoverable and citable, also lead Clarivate to classify them as “citable items”? Dr Udey and Elizabeth Blalock said that they would investigate whether other journals publish abstracts for Letters without leading them to be counted as citable items and, if so, how this is accomplished.

Russell Hall, MD, *JID Innovations* Editor, gave his first report to the Board since the launch of the first issue in March. This new OA journal provides immediate access for both academia and the public at large. Publication fees are \$1,500 for SID European Society for Dermatological Research members and \$2,000 for others. Benefits of the format include no page limit and allowance for sharing of tables, figures, and supplementary data.

A major goal of the new publication is to maintain a high-quality, engaged review process. The *JID Innovations* seeks to include the following types of articles: negative studies, replication of previous data, new applications of technology to skin biology, and small investigator-initiated clinical trials.

There will be a focus on reviews (gaps, future directions) to look forward, not back. There will also be innovation in the process. The Editorial Board will accommodate the preferences of authors, your manuscript, your way. This means that authors can determine the pagination of methods, results, and discussion sections as they see fit.

In terms of manuscript sources, many are triaged from the JID if rejected. Emphasis will be placed on reviewing the approach: “How important is the question the research addresses?” “Are the methods suitable to answer it?” “Is the discussion justifiable?”

Dr Hall was very pleased with the newly formed global editorial board, which includes geographic and gender diversity and rising stars in the research community. The *JID Innovations* deployed a poll on negative results and replication on Twitter. Since the launch of the Journal in October 2020, it has received 120 total submissions. To date, 27 have been accepted, and 22 have been rejected. New publications require 25 publications to be indexed, so that task is complete. So far, over 1,500 articles have been downloaded. Given the successful growth of the *JID Innovations*, the Editorial Office may need to grow to maintain its production and turnaround standards. Dr Hall finished by thanking the Board and collaborators for their support and confirming his commitment to reaching a wide readership.

Governance

Dr Fairley asked board members for approval or discussion of reports from standing and ad hoc committees included in the Consent Agenda. A motion was made to approve; it was seconded and approved. Next, she reviewed the recently revised process of electing directors. The finalists from the online voting for two new directors were Cassandra Quave, PhD and Lloyd Miller, MD, PhD. They were unanimously approved by the Board. They will be ratified through a vote of members present at the SID Business Meeting on Friday, May 7, 2021.

Nicole Ward, PhD, Secretary-Treasurer, reviewed the history and process for selection of the inaugural Freinkel Diversity Fellows. Members of the Diversity and Inclusion Committee had reviewed all candidates and put forth a slate of recommended candidates for the award. The Board reviewed the slate, which included Angel Byrd, MD/PhD (Howard University) and Felicite Noubissi, PhD (Jackson State University). A motion to approve the finalists was made, seconded, and approved.

Dr Ward then described the activities of the JID Editor Search Committee. A call for nominations was sent out in the fall of 2020. Six candidates submitted a Letter of Intent, and from those, three (Alice Pentland, Chris Griffiths, and Erwin Tschachler) were requested to submit full proposals by the April 1 deadline. Two full proposals were received (from Drs Pentland and Tschachler), and both were interviewed through Zoom on April 16. After discussion, the committee recommended Erwin Tschachler, MD, as the next JID Editor, his term beginning June 1, 2022. A motion to approve Dr Tschachler as the next JID Editor was made, seconded, and approved with three abstentions.

Educational Programs

Jim Rumsey, SID Chief Operating Officer, reviewed the 2021 meeting abstract statistics, an overview of various sessions and lectures that would be broadcasted simu-live in the virtual meeting programming and that all sessions will be available for on-demand viewing through May 31. Additional details were included in the Consent Agenda materials. The

2021 Budget featured a break-even attendance of 700, and total registration exceeded 1,300. Meeting registration had already surpassed the budgeted amount of \$218 thousand by nearly \$40 thousand.

Dr Fairley discussed the launch of her “Networking & Mentoring Circles.” Over 80 people signed up as mentors/mentees. There was varying success in the interaction, and the format will be revised to fit the needs of the members. A survey will be deployed to gather information on what worked and what did not.

Further discussion centered on additional virtual programming.

Finance

Mr Rumsey provided an overview of fiscal year (FY) 2020 final figures, including a significant surplus of \$203 thousand. He explained that the surplus was a mixture of cutting expenses related to the planned Scottsdale meeting and additional income from the receipt of a PPP loan of \$139 thousand, salvaging continuing medical education (CME) grants for the virtual meeting of \$219 thousand, and donated registration fees from the 2020 SID meeting of \$75 thousand. Overall, the variance to the total approved FY 2020 Budget Income was \$1.6 million; the original approved budget included a modest surplus of \$65 thousand. The entire Board expressed their thanks and praised Mr Rumsey and the entire SID staff for their accomplishment.

Development/fundraising

Becky Minnillo, DM/MPA, Chief Program and Development Officer, gave the Board updates on 2021 fundraising progress to date; efforts focused on CME grants and sponsorship for the virtual meeting. She pointed out that in contrast to previous years, meeting sponsor funds far exceeded CME levels (\$168 thousand vs. \$35 thousand, respectively). The focus for the remainder of FY2021 will be to secure additional Industry Corporate Members at the \$10 thousand and \$25 thousand levels. These funds can support travel awards, Diversity and Inclusion (D&I) activities, and other activities/programs. She proposed that there would be a perceived value in establishing an Industry Advisory Council that is included with membership. Jean-Phillippe Therrien, PhD, offered to serve on the committee, and Lloyd Miller, MD/PhD, was suggested as a co-chair. The Board made a motion to establish this ad-hoc Industry Advisory Council; it was seconded, and approved.

The committee’s charges were noted to (i) interact more dynamically with industry researchers to hear their needs and share our needs and (ii) identify ways to support the SID and increase corporate membership and sponsorship offerings. This is to be bi-directional and a mutually beneficial partnership.

SOCIETY BUSINESS

Outreach

Dr Ward reviewed the recent activity of the International Societies for Investigative Dermatology (ISID), including planning for the 2023 ISID meeting. The Japanese Society for Investigative Dermatology is being pressed to provide detailed fundraising plans and an updated budget. The newly formed Audit and Finance Committees are monitoring these financials and will report to the ISID Board. It has not yet been decided whether the format will be in-person only or hybrid (more likely).

New Business

A date for the fall SID Board meeting needs to be selected. A Doodle poll will be sent out by the SID Office to find the best date; this will be late September/early October to avoid conflicts with holidays, etc.

Dr Ward raised the topic of Board voting for committee election. The Board will be given a list of current Standing Committee Members and their expertise. The Committee on Scientific Programs requires a broad array of expertise to span all abstract categories and emergent areas of science. The Committee on Education also requires diverse research acumen, as they develop programs intended to complement the rest of the meeting and other audiences (retreat, etc.).

After some discussion, the Board agreed on the following process:

- Before the fall meeting, send the Board a list of all standing and ad-hoc committees (with open positions highlighted) describing the expertise of the committee members and gap areas (BOD can add to the gap areas).
- Send out an RFA that includes a choice of committee(s) the applicant is willing to be on; collect keywords and Biosketches.
- BOD Members to recruit candidates one on one to encourage people to apply, who they feel fit the committee charges, area of expertise, etc.
- Doodle to BOD—to identify the committees for which they want to review applicants—and an ad-hoc Board Review Committee will be formed for each Committee.
- These ad-hoc committees will receive applications and review them—each committee may want to meet before the BOD meeting to rank their candidates and decide how many to present and which applicants to the entire BOD.
- At the BOD meeting, members who reviewed each standing/ad-hoc committee will present their finalists to the entire BOD for a vote.
- During the BOD meeting, Dr Minnillo will use Zoom polling to collect the votes—and committee membership will be filled according to the top votes.

Mr Rumsey discussed the format for the 2022 meeting and the likelihood that it will need to be presented as a hybrid. Depending on which selections are chosen to be offered in a virtual component, the corresponding A/V costs will be impacted, along with the hotel and Oregon Convention Center contracts.

Many of the Board Members stated that they see the hybrid as an opportunity. They felt that the hybrid would allow those with vaccine hesitancy and those not yet able to travel (international attendees, especially trainees) to participate in the meeting and interact with in-person attendees too. It also offers more residents the opportunity to participate because the Accreditation Council for Graduate Medical Education limits the amount of time they can be away from their clinical training.

It was felt that only lectures in the main room should be recorded. This will leverage the A/V techs already in place (many of the Named and SOTA Lectures from past years have been posted on the SID YouTube channel). In addition, the Concurrent Mini-Symposia and Posters should be in-person-only components.

The existing contracts will need to be renegotiated to achieve some level of hybrid. This decision will need to be made by late summer-early Fall.

Paul Nghiem, MD/PhD, Secretary-Treasurer, shared a draft of an image created by a graphics company called Digizyme. It is intended to enhance the visual aspect of the SID website. Besides representing the skin research conducted by the SID community, it can be utilized as an educational tool. It could also be an additional SID logo displayed prominently at the annual meeting and/or be modified by SID members to reflect the disease state or biology of interest—using it as an initial template.

There was discussion about launching a virtual educational series, as planned in 2020. This could be under the purview of the Committee on Education because it is not abstract driven. Topics can include science, clinical issues, and career development as well as D&I sessions.

To build a more diverse pipeline in the organization and specialty, there must be earlier interventions. This could be like the SIDES program started by Dr Ken Kraemer (and more recently organized by Dr Minnillo until 2016). It was suggested that this option could be explored and potentially resurrected with Dr Sancy Leachman to obtain local connections relating to the 2022 Annual Meeting planned for Portland, OR.

Another suggestion was to provide small research grants to SID Members to mentor URMs, POC from their local high schools, or undergraduates for a summer research project. Other grants could cover medical school student rotations—need \$2,000 SID-sponsored grants. Funds could cover the summer research and SID meeting registration. There are also PhD students who want to learn new techniques; mentors could share research methodology/technology. The SID could engage industry partners in this program, grow the pipeline, and virtual mentor at the company...

Luis Garza, MD/PhD, is starting his appointment term on the National Institute of Arthritis and Musculoskeletal and Skin

Diseases (NIAMS) Advisory Council and suggested that the SID could increase its advocacy efforts. Potential venues include virtual Hill visits and developing an infographic showing how NIAMS funding levels lag most of the other Institutes. This could be shared with the NIAMS Coalition, a group of over 90 patient and professional organizations. Dr Minnillo reminded the Board that she serves on the Coalition Steering Committee and could easily disseminate the piece. Finally, the SID could join forces with the AAD when it holds its Hill Day.

Another discussion topic was to explore the use of some SID funds to provide financial support for young

investigators. Suggested ideas were (i) to learn new techniques and models and (ii) to encourage team science by requiring basic researcher and clinical researcher collaboration.

Other

The Board met in Executive Session. With no further business to discuss, a motion to adjourn was made, seconded, and unanimously approved.

Prepared by Dr Becky Minnillo on 26 May 2021

Society for Investigative Dermatology Board of Directors Meeting

The Society for Investigative Dermatology

September 30, 2021

Held via Zoom Meeting

Present: Lisa A. Beck, MD, Nicole Ward, PhD, Suephy Chen, MD, Valentina Greco, PhD, Maria Morasso, PhD, Andrzej Dlugosz, MD, Cassandra Quave, PhD, Aimee Payne, MD/PhD, Luis Garza, MD/PhD, Maryam Asgari, MD, Janet Fairley, MD; Sewon Kang, MD, Paul Nghiem, MD/PhD, Mark S. Udey, MD/PhD, Daniel Kaplan, MD/PhD, Heidi Jacobe, MD, Niroshana Anandasabapathy, MD/PhD, and Natasha Hill, PhD. Unable to Attend: Leandra Barnes, MD/PhD and Lloyd Miller, MD/PhD.

Invited Guests: Floris de Han (Elsevier), Russell Hall, MD (Editor, *JID Innovations*), and Erwin Tschachler, MD/PhD (JID Editor-Elect).

Lindsey Criswell, MD/MPH (Director, NIAMS) was a special guest. Also attending were Dr Robert Carter (Deputy Director, NIAMS), Cindy Caughman (Branch Chief, Science Planning, Policy and Analysis Branch), Dr Stephanie Burrows (Science Policy Analyst, Science Planning, Policy and Analysis Branch), Dr Gayle Lester (Director, Division of Extramural Research), Dr Alexey Belkin (Program Director, Division of Extramural Research), Dr Ricardo Cibotti (Program Director, Division of Extramural Research), and Dr Hung Tseng (Program Director, Division of Extramural Research).

Staff: Jim Rumsey, Becky Minnillo, DM/MPA and Elizabeth Blalock.

President Lisa Beck called the meeting to order and welcomed the Board. A motion to approve the meeting minutes from the Virtual May SID Board Meeting was made, seconded, and approved.

COI: Dr Beck asked Board Members whether anyone had any COI declarations to make or amend; none were stated. She then provided a brief review of the informational President's Report, which summarized the deliberations of recent Executive Committee calls. She indicated that most of the material contained in the report would be covered at various points of the Board Meeting. She noted that the Consent Agenda document includes information-only materials, and the Board Book PDF features the items that require full Board discussion.

Journal

JID Editor, Mark Udey, provided an overview of the Editor's Report for the group. Although the COVID-19 pandemic continues to impact authors, reviewers, and readers, production and publication schedules have remained on track,

owing to an effective Editorial Office and Elsevier. Submissions were up to 9% in 2020. The Editorial Board has met virtually and remains engaged and productive. The new Social Media Editors have been successful in gaining followers (Twitter: ~4,700 in June 2021). The Editorial Office led by Elizabeth Blalock contributed significantly to the publication of two special issues: one on aging and another on autoimmunity. Dr Udey pointed out that JID staff had identified specific post-acceptance sticking points at which the publication process could gain efficiencies. These have been implemented and/or planned.

The IF for 2020 was 8.551, up from 7.143 in 2019, ranking fourth in all dermatology publications. To continue to generate highly cited papers, more Review and Perspectives articles will be solicited. In addition, the special Aging issue mentioned earlier was published in April 2021, and Editorial Board member Johann Gudjonsson has invited a collection of review articles for the autoimmunity special issue that is set for a March 2022 publication.

More information about the JID Connector and RTMS articles was presented in the written report. Other topics discussed included the production schedule, review times, publication statistics, and updates on manuscript submission statistics. Fast track submission was deployed with the goal of publication within 1 month of submission, which was felt to have increased the IF.

The manuscript revision process was reviewed, and a proposal was developed to address slowdowns in production that can occur owing to the time required to review figures. It included a list of issues considered and a corresponding list of the most pressing issues to address. There was a recommendation to use an image screening service that is accomplished by a human or a combination of artificial intelligence and human review. Details and costs for three of these platforms were included in the proposal.

Erwin Tschachler, MD, Editor-Elect, presented his Editor Transition Report. It provided details and names of those recruited for the Editorial Board (and a description of its structure), Deputy and Section Editors, Associate Editors, RTMS team, and Social Media Editors. This included plans to convene the various teams to discuss and plan for a smooth transition in June 2022.

He informed the Board that he is conducting an ongoing evaluation of current front-half material as well as considering new content types. He relayed that Elsevier is planning a rollout of a responsive new website that will be displayed on any device—mobile, tablet, pad, laptop, etc. He thanked the Board for its support.

Invited Guest Floris de Han, from Elsevier Publishing, provided an overview of the provided Publisher's Report. He shared details of factors that led to the increased IF and reviewed the competition's highly cited articles, including clinical guidelines, clinical trials, population studies, and meta-analyses. A list of the most cited articles in 2020 was also provided, with many falling into the top 1% of articles in clinical medicine.

Board Members asked about the \$2 billion in profit realized by RELX (Elsevier's parent organization) and charges for OA publication. There was a discussion on the rationale for setting the fees and whether authors can include OA charges on their grant application budgets.

Additional data were presented about www.JIDonline.org usage, the most downloaded articles from ScienceDirect for 2020 and 2021 (through July 2021). There was a chart outlining usage for the top 10 countries for the years 2016–2021 YTD and a list of the top 10 most downloaded articles from JIDOnline.org through July 2021. Those with the most Social Media attention were also listed, covering a wide range of research and disease topics.

Mr de Han also provided updates on *JID Innovations*, including topics covered in Dr Hall's report, including indexing, website updates, Marketing and Social Media awareness, and usage. He provided a list of the most downloaded articles through July 2021. Titles encompassed a diverse range of basic, translational, clinical, and epidemiological content. This was compared with the list of most accessed articles from JIDOnline.org, noting that it was a different list. This can help the Editor determine which gains the most traction. He finished with an overview of marketing goals and thanked the Board for their time and attention.

Russell Hall, MD, Editor, *JID Innovations*, gave his report to the Board. He reviewed the activities of the Editorial team since his term commenced. The report provided an overview of Gold OA and what it means for authors, funders, and readers and detailed the scope of the journal as well as the criteria for acceptance of a manuscript. The bios of the Editorial Board were included in the report.

The manuscript transfer process (receiving manuscripts rejected from the JID) was highlighted as an essential element of the *JID Innovations'* success. Transfer can save time in review, and in many cases, the Editor can make a first decision within a week of the transfer.

Associate Editors have also been charged with inviting review articles from recognized colleagues. In addition, *JID Innovations* launched a social media campaign to encourage submissions, including negative studies/case reports. His vision for *JID Innovations* is to adopt the concept of open science, and the team is exploring open review and double-blinded review (as done in the review of abstracts submitted to the SID Annual Meeting). There is evidence of a reduction in bias in double-blinded reviews.

The statistics for all submissions since the launch were provided, revealing a 24% rejection rate and that 59% were transfers from the JID. Since the September 2020 opening of online submissions, a total of 150 have been received.

Dr Hall reviewed the milestones required for indexing, the most important being the publication of 25 articles. The *JID Innovations* achieved this with content in the first two issues. Elsevier applied to PubMed in July and expects an answer by October. This will enable all *JID Innovations* content to be discoverable by readers. He praised the exceptional efforts of Elizabeth Blalock in managing the Editorial Office and her contributions to all areas of *JID Innovations*. In addition, he acknowledged Sarah Forgeng for her contributions to journal design, submission platform function, marketing, and more.

NIAMS

Invited guest Lindsey Criswell, MD/MPH (newly appointed Director, NIAMS), was introduced to the Board and thanked the leadership for providing the opportunity to interact with the organization. She presented an overview of major NIAMS and National Institutes of Health (NIH) initiatives, starting with the proposed President's FY 2022 Budget that includes an overall increase to NIH of 21% FY 2021 and a 7.2% increase for NIAMS (including by \$24 million to enhance pain and opioid research).

The proposed ARPA-H entity intended to be housed within the NIH umbrella was detailed, and there were 15 listening sessions with Francis Collins (who thanked Becky Minnillo, Chief Program, Communications, and Development Officer for representing the SID during the Advocates for Research on Aging, Arthritis, and Musculoskeletal and Skin Disorders session). In terms of D&I, the NIH has made a concerted effort to focus on diversity in both the Intramural and Extramural programs in the UNITE Initiative. In addition, the Diversity Supplement has been increased to help stakeholders function as a cohort.

The Clinical K Forum will be held virtually in December to allow both NIAMS and invited organizations, including the SID (Becky Minnillo will attend) to understand how to provide effective support to young investigators engaged in clinical research. She covered the Accelerating Medicines Partnership of NIAMS National Institute of Allergy and Infectious Diseases, which includes Industry and Nonprofit partners, aimed to pursue rheumatic arthritis and Lupus targets and develop new drug candidates. Finally, she reviewed the NIH Data Sharing Policy, the NIAMS strategy for data science, and the planned Inflammation Resolution Roundtable (scheduled for November), all designed to advance the research horizon and facilitate the sharing of complementary knowledge among stakeholders.

Dr Criswell closed her presentation by inviting the SID Board to consider the following: exciting skin research and how to partner with NIAMS, how we can support trainees and early-stage investigators, and how we can enhance

SOCIETY BUSINESS

workforce diversity and address health disparities in our shared mission areas. There was discussion about promoting interdisciplinary science and identifying synergies, including Inter-NIH ICs because many in the SID community are funded by institutes outside NIAMS. The Board thanked Dr Criswell and the other NIAMS attendees for providing these updates.

Governance

The informational reports from Standing Committees—Membership, Education, Scientific Programs—were briefly reviewed. Dr Beck did ask the Board to consider upgrading their membership (if not already) to the Patron level..., which helps to further support the organization.

Vice President Sewon Kang reviewed the Audit Committee report with the Board. Discussions ensued regarding the contents of the report and the recommendations made by the Auditing firm. A motion was made to approve the report. Maria Morasso and Natasha Hill abstained from voting on the approval of the report owing to NIH guidelines. The motion was seconded, and the balance of the board was unanimously approved.

The Board reviewed the report from the Committee on Nominations, which provided a slate of proposed board officers for 2021. The Board engaged in discussion and a series of voting rounds to select the following: President-Elect: Lynn Cornelius, MD; Vice President-Elect: Mÿ Mahoney, PhD; and Resident Board Representative: Abbey Perl, PhD. A slate of seven board director candidates was also presented. The names included Mary-Margaret Chren, MD; Doug Grossman, MD/PhD; Johann Gudjonsson, MD/PhD; Valerie Horsley, PhD; Eleni Linos, MD/MPH; Ginette Okoye, MD; and Eric Simpson, MD/MCR. A motion was made to accept the entire slate, seconded, and unanimously approved. All the Board Director finalists will be contacted and congratulated as Nominees for the Director slots. Those who accept will submit a biography and vision statement and be carried forward for an online vote by SID Members in the Spring of 2022. An official vote will occur in conjunction with the SID Business meeting..., which will be held during the 2022 SID Annual Meeting.

Standing Committee Openings. Nicole Ward, Secretary-Treasurer, reviewed the newly implemented voting process to fill the vacancies in SID Standing Committees. Small ad-hoc review groups were formed and selected a slate of finalists to be considered for each opening on standing committees. The Board discussed the candidates for the various committees, cast a series of votes through Zoom polls, and approved the following: P. Therrien, PhD for Audit Committee and Janet Fairley, MD for Committee on Nominations for a 3-year term (2022–2025); Rhoda Alani, MD; Xioamin Bao, PhD; and Cory Simpson, MD/PhD for Committee on Scientific Programs for three 5-year terms (2022–2027); Jillian Richmond, PhD and Kevin Wang, MD/PhD for Committee on Education for two 5-year terms (2022–2027); and Felicite Noubissi, PhD and Joy Wan, MD for Committee on Membership (2022–2025).

Ad-hoc Committee Reports

D&I. A draft statement concerning recent articles on Albert Kligman was reviewed and discussed. Several edits were made, and the Board agreed to publish a final statement regarding past SID involvement with Dr Kligman and his foundation. It was also agreed that the SID Office would distribute the draft to the entire Board for final edits before it is published to the membership and community at large.

A review of D&I Committee activity was presented, including an update on the inaugural Freinkel Fellows and other diversity initiatives, including support for Project IMPACT and the creation of a Diversity Plan submitted with the R13 application to NIAMS to support the Retreat. The list of new members was also presented to the Board. After further discussion, a motion was made to elevate the Ad-hoc Committee to a Standing Committee. This was seconded and approved unanimously. It was noted that the charges for the new Standing Committee should be drafted. The group agreed, and the bylaws change establishing D&I as a Standing committee will be voted on during the 2022 SID Annual Meeting.

Educational Programs

Jim Rumsey, Chief Operating Officer, provided a review of updates for the 2022 SID Annual Meeting, including the names of those selected for Named and State-of-the-Art Lectures, Abstract Categories (and Concurrent Sessions assigned by day), timeframes associated with the abstract submission, and initial and final reviews. He also summarized the various scenarios for the meeting format (in-person, hybrid, and virtual offerings). The Board agreed that it is too early to determine exactly which format(s) will be employed. The status of current COVID-19 will be closely monitored, and a final decision will be made around the first of the new year. Detailed updates will be provided to the Executive Committee in the interim. Options for verifying vaccine status for all attendees were also presented, along with concerns regarding safety in Portland.

Dr Minnillo provided updates on the nonabstract sessions planned. This includes a Food and Drug Administration session, Blank Forum (Single Cell Analyses-Immune Mediated Skin Diseases), Clinical Scholars/Outcomes (Clinician-led Investigation and New Therapies), and two Translational Symposia: translational I (Artificial Intelligence, Big Data, and Medical Informatics) and translational II (Drug Reactions and Repurposing). Speakers are being confirmed, and soon, the Retreat Planning Committees will be convened to identify faculty and create a program for both the Resident and PhD Retreats.

In terms of other new programs, Dr Beck shared that she and Dr Minnillo are expanding on the Networking and Mentoring Circles started by Dr Fairley during her term. Applications will open in October. Dr Kang had conducted a podcast interview, and it will be released in October (Dr Minnillo is still finalizing the technology needed to provide online access to the new series.) More are planned in the future and will cover a wide array of topics and speakers.

Finance

Mr Rumsey presented the Finance report prepared by the Committee Chair, Louis Faló, to the Board, which detailed items of note for the FY 2021 YTD budget and the surplus projected. The Board reviewed the Committee’s assessment and recommendation of the proposed 2022 SID Operating Budget that estimated a modest surplus. The budget overview listed new initiatives and requested allocation of Board-directed funds, including \$200 thousand for Bridge Awards, \$139 thousand for JIDI Editorial/Production expenses, \$15 thousand for Freinkel Fellowships, and \$40 thousand for Travel Awards to the 2022 SID Annual Meeting. After deliberation, a motion was made to approve the proposed FY 2022 Operating Budget. The motion was seconded and unanimously approved. Maria Morasso and Natasha Hill abstained from voting owing to NIH employee guidelines.

Development/fundraising

Dr Minnillo spoke to the group about development efforts on behalf of the SID for the year, including plans for fundraising efforts for 2022. She asked the Board to facilitate introductions to industry contacts from companies that might be interested in partnering with the SID in 2022 and the ISID in 2023. Efforts for 2022 will focus on CME grants, Sponsored Symposia, multiple technology-based sponsorship opportunities, and expanding Corporate Membership. In addition, she would try to recruit sponsors for the SID News and other online content. Finally, she also reminded the group of the approved plan to create an Industry Advisory Council and that JP Therrien had offered to work with her on developing this initiative.

Alliances/collaborations

Brief updates on the planning for the inaugural 2023 ISID Meeting were provided. The ISID Board is scheduled to convene in early October, and more plans will be finalized at that time. Dr Minnillo has been working with the Japanese Society for Investigative Dermatology hosts and Chris Griffiths to commence with fundraising.

The SID continues to manage the Medical Dermatology Society (MDS). The MDS contract ends on December 31, 2021, and a new 1-year contract has been submitted to the group for renewal.

New Business

Paul Nghiem, Secretary-Treasurer, shared the revised image produced by Digizyme that will be posted to the SID website. All felt that the graphic adequately reflected the diverse makeup of the skin visually, thus representing the broader SID skin research community. Final tweaks will be made, and the image will be used for various branding, marketing, and educational purposes in the future.

The topic of short- and long-range planning was brought forth. It was noted that the last plan implemented was in 2003. A second strategic planning retreat was held in 2007 but never implemented. There was consensus that with the recent

COVID-19 impact on significant aspects of the organization’s functions, especially its finances, it would be wise to consider developing a roadmap for the next 2 or 3 years. Setting milestones will enable the SID to measure its success in tangible terms. A small group of the leadership will continue discussions on the potential size, scope, and timing of such a process.

Further discussion centered on the creation of a lectureship for URM’s. The intent would be to showcase the research of URM’s in the research community. This issue was debated because some feared that it may have the opposite effect by making selected speakers feel as if their work was not an expert in their field, thus not selected for other prestigious SID talks such as Named or SOTA Plenary Lectures.

The SID and JID staff were thanked and excused, and the Board met in Executive Session.

With no further business to discuss, a motion to adjourn was made, seconded, and unanimously approved.

Prepared by Becky Minnillo on October 13, 2021.

Table I. Attendance at Annual Meeting

Year	Attendees
1988	600
1989	1,200
1990	930
1991	960
1992	1,058
1993	1,131
1994	1,217
1995	1,282
1996	1,316
1997	1,206
1998	1,911
1999	1,230
2000	1,159
2001	1,368
2002	1,266
2003	1,898
2004	1,554
2005	1,475
2006	1,530
2007	1,443
2008	1,528
2009	1,142
2010	1,346
2011	1,350
2012	1,339
2013	2,400
2014	1,208
2015	1,127
2016	1,281
2017	1,606
2018	2,332
2019	1,641
2020	1,631
2021	1,342

Table II. Membership, 2000-2021

	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
Active	1213	1201	1178	1167	1188	1150	1146	1152	1054	1033	1050	1118	1172	943	1058	1038	1012	1149	1051	1062	544	873
Patron	197	219	214	211	205	207	221	276	266	228	126	89	75	60	67	63	65	60	64	69	62	64
Individual	30	33	37	24	29	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Corporate	12	10	7	1	1	3	3	3	4	2	2	2	2	3	2	2	4	3	3	3	2	2
ESDR/SID	42	40	41	39	41	42	46	66	67	71	65	66	66	70	52	56	56	66	66	67	66	37
Residents/Fellows	100	117	109	108	130	110	120	150	146	141	123	123	106	318	199	180	267	314	251	624	366	633
Honorary	47	47	47	50	46	48	47	47	48	53	58	48	53	57	59	65	60	62	68	70	73	74
Life Member	12	24	24	21	24	28	30	30	31	12	29	53	47	37	32	38	39	40	41	41	5	51
Total	1,653	1,691	1,657	1,621	1,664	1,588	1,613	1,724	1,616	1,540	1,453	1,499	1,521	1,488	1,469	1,442	1,503	1,694	1,544	1,936	1,162	1,734
Membership																						

Table III. Balance Sheet as of December, 2021 (Un-Audited)

Income		
Dues	\$	2,45,245
Registration Fees		2,91,557
Journal Income		17,22,886
Other Income		2,55,945
Contributions		3,61,147
Total Income		28,76,780
Expenses		
SID Office	\$	3,39,567
JID Office		10,67,031
Annual Meeting		4,57,733
Committees		1,42,506
Other Expenses		4,89,825
Total Expenses		24,96,663
Net Income (Loss)		3,80,117

Table IV. Income Statement for Year Ending December 31, 2020

**The Society for Investigative Dermatology
Statement of Financial Position
December 31, 2020**

		2020
ASSETS		
Cash & cash equivalents	\$	\$44,85,919
Investments in marketable securities		\$42,54,224
Royalty/Mgmt. Fees receivable		\$1,35,781
Prepaid expenses		\$1,18,614
Deposits		\$0
Property and equipment net of accumulated depreciation		\$0
TOTAL ASSETS		\$89,94,538
LIABILITIES		
Unearned revenue		\$79,296
Accounts payable		\$3,86,619
NET ASSETS		
Unrestricted		\$53,69,931
Temporarily restricted		\$31,58,692
NET ASSETS		\$85,28,623
TOTAL LIABILITIES AND NET ASSETS		\$89,94,538

Table V. Current cash assets, December 31, 2021 (Un-Audited)

	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
Operating Fund*	\$8,37,604	\$10,61,683	\$13,07,527	\$7,42,597	\$11,85,461	\$19,83,537	\$23,06,679	\$32,46,295	\$38,99,212	\$34,78,855	\$39,72,627	\$41,44,765
Named Funds												
Beerman*	\$70,753	\$69,211	\$76,119	\$87,183	\$94,747	\$91,645	\$1,01,020	\$1,21,556	\$1,15,366	\$1,48,340	\$1,72,156	\$2,20,434
Blank*	\$61,481	\$60,143	\$68,196	\$80,093	\$87,017	\$79,895	\$81,069	\$97,414	\$92,410	\$1,18,897	\$1,37,787	\$1,76,066
Montagna*	\$76,570	\$74,388	\$82,987	\$1,01,064	\$1,11,262	\$1,09,698	\$1,21,018	\$1,46,059	\$1,38,728	\$1,78,883	\$2,07,681	\$2,66,450
Kanof*	\$61,657	\$54,202	\$59,645	\$76,338	\$82,031	\$82,586	\$92,646	\$1,11,838	\$1,06,262	\$1,39,467	\$1,61,931	\$2,07,567
Katz**	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$2,94,245	\$3,69,845	\$3,77,025
Stone*	\$89,157	\$90,179	\$92,513	\$91,256	\$90,508	\$87,523	\$89,774	\$92,272	\$90,103	\$96,913	\$1,04,897	\$1,03,113
Farber**	\$2,67,437	\$2,54,786	\$2,91,930	\$3,79,712	\$4,34,915	\$4,38,825	\$4,24,312	\$5,11,141	\$4,58,663	\$5,80,511	\$6,77,510	\$8,04,185
Kligman/Frost	\$53,161	\$53,335	\$45,009	\$45,069	\$45,141	\$45,207	\$45,252	\$45,297	\$45,343	\$386	\$0	\$0
Misc.*	\$19,150	\$66,622	\$85,346	\$1,91,996	\$2,24,382	\$2,20,993	\$2,33,176	\$2,47,503	\$6,33,150	\$6,54,941	\$6,72,556	\$6,60,160
JID Fund*	\$6,60,449	\$6,63,469	\$7,67,461	\$10,05,776	\$11,43,094	\$11,39,349	\$12,43,549	\$15,02,695	\$14,12,449	\$18,39,613	\$21,39,332	\$27,08,034
Total	\$21,97,418	\$24,48,016	\$28,76,734	\$28,01,085	\$34,98,558	\$42,79,257	\$47,38,496	\$61,22,071	\$69,91,686	\$75,31,051	\$86,16,322	\$96,67,800

*Board Directed Funds

**Restricted Funds